AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma & Immunology. In each bi-monthly episode, hosts Gerald Lee, MD and Stanley Fineman, MD invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Site
RSS
Apple
Data updated on 04/07/2026
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Discover shows related to allergytalk, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Episode 48 - Can Blood Transfusions Trigger Food Allergy?
Episode 76
Thursday, January 16, 2025 • Duration 19:19
Welcome to Season Three of Allergytalk!
Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE
Episode 75
Friday, December 13, 2024 • Duration 12:44
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI
Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment
Episode 74
Friday, December 13, 2024 • Duration 20:13
Episode 2: Overcoming Barriers in HAE Treatment
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI
This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Create effective treatment plans for their specific population (minority, rural, urban)
Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI
This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Episode 47: Does Food Allergy Increase Cardiovascular Risk?
Episode 72
Friday, December 13, 2024 • Duration 24:57
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
CRISPR Gene-Editing Therapy for Hereditary Angioedema
Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.
Episode 46: Can We Achieve Clinical Remission In Asthma?
Episode 71
Friday, December 13, 2024 • Duration 24:35
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.
Clinical Remission in a Real-World Severe Asthma Registry
McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3
Episode 70
Thursday, October 17, 2024 • Duration 22:44
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
No relevant financial relationships with ineligible companies to disclose
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 2
Episode 69
Thursday, October 17, 2024 • Duration 18:33
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
No relevant financial relationships with ineligible companies to disclose
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 1
Episode 68
Thursday, October 17, 2024 • Duration 13:31
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 1: The Limitations of Bronchodilator Only Rescue Therapy
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.
Please rate our podcast on Apple podcasts!
Please give us feedback, corrections, and suggestions!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)
More Evidence Against Using Corticosteroids for Anaphylaxis
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)
